Pericleous Marinos, Caplin Martyn E, Tsochatzis Emmanuel, Yu Dominic, Morgan-Rowe Luke, Toumpanakis Christos
Neuroendocrine Tumour Unit, ENETS Centre of Excellence.
Sheila Sherlock Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, London, UK.
Asia Pac J Clin Oncol. 2016 Mar;12(1):61-9. doi: 10.1111/ajco.12438. Epub 2015 Dec 14.
Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are established treatments for symptom control in patients with advanced neuroendocrine tumors (NETs) with significant hepatic tumor burden.
To assess efficacy, toxicity and survival parameters in NET patients undergoing TAE and TACE.
A retrospective analysis was carried out of 50 patients with NETs, who underwent a total of 67 embolization procedures in a period of 9 years. All patients had symptomatic and/or radiological progression, despite previous treatments.
Symptomatic improvement was observed in 75% of patients who underwent TAE and 57% of patients who had TACE (P = 0.36). Radiological response was observed following 73% of embolization treatments delivered and specifically in 82% of all TAE and 62% of all TACE procedures (P = 0.46). Plasma Chromogranin A (CgA) levels were reduced in 65% of the patients following embolization. Patients with increasing serum CgA levels after treatment had reduced median overall survival (OS) and progression-free survival (PFS) (P = 0.0001). Patients on somatostatin analogs (SSAs) at the time of treatment had improved OS (P = 0.013), but not PFS (P = 0.216). Overall, the differences in OS (P = 0.21) and PFS (P = 0.19) between one mode of treatment over the other were not found to be statistically significant. One- and 5-year OS were 65% and 41% for TACE and 90% and 57% for TAE, respectively. The commonest complication was postembolization syndrome and mortality was 4%. Overall, the complication (P = 0.18) and mortality rates (P = 0.22) were not significantly different between TAE and TACE.
TAE/TACE are beneficial treatments for control of symptoms as well as tumor growth, with acceptable morbidity and mortality rates. No significant efficacy and survival differences were shown between TAE and TACE. Posttreatment CgA levels and the concurrent use of SSAs were independently associated with survival.
经动脉栓塞术(TAE)和经动脉化疗栓塞术(TACE)是治疗晚期神经内分泌肿瘤(NET)且肝肿瘤负荷较大患者症状控制的既定疗法。
评估接受TAE和TACE治疗的NET患者的疗效、毒性和生存参数。
对50例NET患者进行回顾性分析,这些患者在9年期间共接受了67次栓塞手术。尽管此前接受过治疗,但所有患者均有症状性和/或影像学进展。
接受TAE治疗的患者中有75%症状改善,接受TACE治疗的患者中有57%症状改善(P = 0.36)。73%的栓塞治疗后观察到影像学反应,具体而言,所有TAE治疗中有82%、所有TACE治疗中有62%观察到影像学反应(P = 0.46)。栓塞后65%的患者血浆嗜铬粒蛋白A(CgA)水平降低。治疗后血清CgA水平升高的患者中位总生存期(OS)和无进展生存期(PFS)缩短(P = 0.0001)。治疗时使用生长抑素类似物(SSA)的患者OS改善(P = 0.013),但PFS未改善(P = 0.216)。总体而言,两种治疗方式之间的OS(P = 0.21)和PFS(P = 0.19)差异无统计学意义。TACE的1年和5年OS分别为65%和41%,TAE的1年和5年OS分别为90%和57%。最常见的并发症是栓塞后综合征,死亡率为4%。总体而言,TAE和TACE之间的并发症(P = 0.18)和死亡率(P = 0.22)差异无统计学意义。
TAE/TACE是控制症状以及肿瘤生长的有益治疗方法,发病率和死亡率可接受。TAE和TACE之间未显示出显著的疗效和生存差异。治疗后CgA水平和SSA的同时使用与生存独立相关。